CEO Update - 8 January 2024

Pre-JPM news comes from London

It was great to see the key pre-JPM news this week announced from London, as the biotech world descended on San Franciso for the annual conference.  

A digital biology company headquartered in London, Isomorphic Labs has announced two large pharma deals with Eli Lilly and Novartis worth nearly $3 billion in combined deal value, just more than two years after launching within Alphabet.

Their British founder is Demis Hassabis, who concurrently leads DeepMind, and Isomorphic Labs' Chief Scientific Officer is Miles Congreve, PhD, former director of chemistry at Astex Pharmaceuticals and an ex-GSK medicinal chemistry leader.

The two separate deals focus on exploiting Google DeepMind’s AlphaFold AI tech, the foundation of Isomorphic’s platform. It predicts protein structure, enabling potentially faster target discovery and compound construction and newer iterations of AlphaFold are expanding beyond protein predictions to include small molecules and nucleic acids. 

Lilly is handing over $45 million upfront to discover small molecule therapies aimed at undisclosed disease targets with more than $1.7 billion in milestone payments. The deal with Novartis is similar, including $37.5 million in upfront cash.

I look forward to seeing further announcements through the week as signs of US economic growth and a wave of M&A deals at the end of last year have boosted sentiment in our sector.

Congratulations to Dan Mahony on new role at Novo Holdings

BIA Chair Dan Mahony has joined the Growth Investments team at Novo Holdings. Based in London, Dan will lead its Growth initiatives in Europe. Dan will continue to serve as Chair of our Association as well as Director of the Wellcome Trust Sanger Institute and the UK Government’s Life Sciences Envoy.

He can now put his long experience as both an investor and analyst to good use. Novo Holdings is a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.  

BIA grows membership, makes new Board and staff announcements

In more internal news, I’m excited to share that this week the BIA has reached 600 companies in membership for the first time ever and has made new Board and staff appointments for 2024. The 600th member company to join BIA is Exscientia, a precision medicine company using artificial intelligence (AI) to revolutionise the discovery and development of new drug candidates. Exscientia is a UK life science scale-up success story, founded by Professor Andrew Hopkins CBE FRS FMedSci (who has been awarded a CBE in the 2024 New Year Honours list) with fellow innovators in 2012 as a spinout from Dundee University. Early Biotechnology and Biological Sciences Research Council (BBSRC) funding proved crucial to demonstrating the potential and practicality of using AI-led approaches and underpinned Exscientia’s formation and early development. In October 2021, Exscientia was floated on the Nasdaq stock market, raising $510 million, the largest initial public offering for a European biotech ever. From small beginnings, with just five staff, Exscientia now employs over 400 people. Headquartered in England at the Oxford Science Park, Exscientia has a diverse global team with offices and labs in Scotland, Austria and the US.

As a member-owned not-for-profit, BIA member companies choose Board members through an annual election. The new representatives joining the BIA Board this month for a three-year term are Ros Deegan, CEO of OMass Therapeutics, Shaun Grady, SVP Business Development Operations at AstraZeneca and Laura Lane, Vice President, Lilly Ventures (Head of Europe) of Eli Lilly and Company adding to the considerable industry expertise that the BIA Board can draw on.

Following an internal restructuring in the BIA’s professional team, with me taking on a more external focus, I’m delighted to announce that Jane Wall has been promoted to Managing Director with a remit to drive the strategic growth of the Association. Nick Gardiner as Chief Operating Officer completes the senior leadership team.  

Details of further changes as part of the restructure of the Association including a new layer of leadership, reporting to Jane, are available in our press release.

It’s fantastic to see the growth of our Association to over 600 members through 2023. I’m delighted that we have been able to develop and promote our talented team at the BIA delivering for members on influence, connection and business solutions. We are well set to respond with agility to whatever 2024 throws at our sector – whilst at the same time developing the core strategic priorities of our membership.

MHRA update

The new international recognition procedure (IRP) is live as of January 2024 – developers of new medicines can now submit applications in accordance with the MHRA Guidance. The IRP, which is expected to speed up the licensing process and bring life-saving medicines to UK patients, has been developed by the MHRA with input from industry including the BIA after the UK left the EU. It allows the agency to take into account the expertise of trusted regulatory partners in other countries, including Australia, Canada, the European Union, Japan, Switzerland, Singapore and the United States, when authorising medicines. Members may find useful the recording of the MHRA webinar to plan their applications via this new route.

The MHRA is holding a webinar on the Innovation Accelerator services on 7 February 2024, providing the latest information about how to access the service and what support is available at an early stage in product development, helping developers of innovative products to understand and navigate the journey from development to marketing authorisation and beyond. The Innovation Accelerator functions bring together the Innovation Office, the Regulatory Advice Service for Regenerative Medicines, Regulatory Science and horizon scanning. Members can register to take part.

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

RSSL announces new Biotech Innovation Hub

RSSL, a leading pharmaceutical contract research organisation, has today announced plans to launch its new Innovation Hub, a dedicated platform to help small- and medium-sized biotech organisations de-risk and accelerate the development of cutting-edge products.

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

CEO Update - 20 February 2024

I'm looking forward to the BIA Committee Summit this week. It will be great to see 200 members in Westminster at one of the most lively and insightful events we do each year. I know it's the volunteer expert army that gives the BIA its unique impact with government and it's always great to understand the committee's priorities and the ideas at the intersection between committees that arise from the event.

Beyond health: why BIA is championing the biorevolution 

The BIA has named this frontier of science Deep Biotech. Our brand-new report, "Deep Biotech: Disruptive innovation for global sustainability" highlights how deep biotech is key to creating a sustainable UK bioeconomy and making the UK a science superpower that benefits all. 

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

Recent decision from the EPO smooths the way to obtaining patents in Europe

The BIA’s Intellectual Property Advisory Committee (IPAC) helps BIA understand and shape the environment for IP ownership to ensure strong protection for BIA member companies. Our EU policy subcommittee has taken a look at what a recent European decision means for the right to claim priority to an earlier filed patent application. This blog sets out some of the details of the case, and the practical implications for BIA members.​​​​​​​

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

CEO Update - 12 February 2024

It was great to see the hugely positive response we’ve had to the launch of our new report "Deep Biotech: Disruptive innovation for global sustainability". I believe we're on the cusp of a biorevolution powered by Deep Biotech, and I want our Association at the forefront of shaping the future of Deep Biotech and championing its disruptive potential.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Enter the dragon: Exploring China’s life sciences market

Next week, Chinese people across the world will be celebrating Chinese New Year. This is the “year of the dragon”, a symbol of strength for the Chinese people. It also represents prosperity, a value Chinese strive for across aspects of life, society and business.

More within